Reporting directly to NERI President, Sonja McKinlay, Ph.D., Dr. Li will manage clinical research operations and all aspects of the company�fs clinical trials, registries and related initiatives. While working to propel its commercial presence, Dr. Li will leverage NERI�fs robust portfolio of federally- funded research in a variety of medical specialties „Ÿ ranging from cardiology and endocrinology to pediatrics, neurology, and men�fs health „Ÿ to solidify its CRO capabilities.

�gWe are thrilled that Dr. Li will have a direct impact on our next decade of growth,�h said McKinlay. �gAs a scientifically-driven organization, we all embrace clinical research with a deep sense of integrity and passion. Our clients appreciate our approachable work style and hands-on senior-level involvement,�h continued McKinlay. �gWith this long-standing prescription for success, we continue to foster seamless internal and external professional relationships and are confident that we can contribute to the achievement of both private and public sector research in the years to come.�h

Prior to her new role as Vice President of Clinical Research, Dr. Li served as Principal Research Scientist and Clinical Director at NERI. Most recently, she led a large, global Phase III clinical trial in heart failure. It involved 4,500 patients and more than 200 clinical centers in North and South America as well as Eastern Europe. Before joining NERI, Dr. Li spent 14 years in the private sector, most recently at the Director level at Wyeth Research working in the Translational Research Department. In that position, Dr. Li coordinated efforts to incorporate pharmacogenomics into clinical trials.

Dr. Li is an Adjunct Associate Professor at Brown University in the Department of Pharmacology, Physiology, and Biotechnology. She maintains an exceptional publication record of first-authored papers, presentations, and abstracts as well as co-authorships of book chapters. Dr. Li has a doctorate from Johns Hopkins in Biomolecular and Chemical Engineering.

NERI is a global, privately held specialty CRO that provides customized clinical trial solutions and patient registry services to pharmaceutical, biotechnology, biomaterial and medical device companies. NERI also has notable experience collaborating on federally-funded research with organizations like the National Institutes of Health (NIH). Since its founding in 1986, NERI has earned widespread recognition for its scientific credibility, efficiency and expertise in conducting clinical trials in a variety of medical specialties. NERI has an impressive track record working on Phase II, III and IV multi-site clinical trials. For more information, visit www.neriscience.com.